Promising data on insulin degludec and LY2605541 at EASD meeting

New data presented yesterday at the Annual Meeting of the European Association for the Study of Diabetes (EASD), being held in Berlin, Germany, show that patients with type 2 diabetes starting insulin therapy had a 43% lower rate of night-time hypoglycemia when using Danish diabetes major Novo Nordisk’s (NOV: N) insulin degludec compared with those using insulin glargine (0.27 [insulin degludec] versus 0.46 [insulin glargine] episodes per patient per year, p<0.001) with equivalent improvements in glucose control.